Skip to main content
. 2024 Feb 29;18(10):7618–7632. doi: 10.1021/acsnano.4c00550

Figure 8.

Figure 8

Therapeutic benefits of AnCHNPs when used in combination with chemotherapy or immunotherapy, tested in B16F10-tumor-bearing mice. (a–c) Dual therapy with AnCHNPs and carboplatin. (a) Scheme of experiment. On Day 0 and Day 2, animals received carboplatin (i.p., 40 mg/kg on Day 0), followed by i.t. administration of 200 μg/kg AnCHNPs (carboplatin+AnCHNPs; n = 5). PBS alone (PBS) and carboplatin alone (carboplatin) were tested for comparison (n = 5). (b) Average tumor growth, animal survival, and body weight curves. *, p < 0.05; **, p < 0.01. (c) Individual tumor growth curves. (d–f) Dual therapy with AnCHNPs and anti-PD-L1 antibodies, tested in B16F10-tumor-bearing mice. (d) Scheme of the experiment. On Day −2, 0, 2 and 4, animals received anti-PD-L1 antibodies (i.p., 10 mg/kg), followed by i.t. administration of 200 μg/kg AnCHNPs (αPD-L1+AnCHNPs; n = 5). PBS alone (PBS) and anti-PD-L1 alone (αPD-L1) were tested for comparison (n = 5). (e) Average tumor growth, animal survival, and body weight curves. *, p < 0.05; **, p < 0.01. (f) Individual tumor growth curves.